Subcutaneous immunoglobulins with rHuPH20 in multifocal motor neuropathy

Completed

• Conditions: inflammatory neuropathy; disease of nerves caused bij the immune system; 10034606

• Registration Number: NL-OMON44726
• Lead Sponsor: niversitair Medisch Centrum

Brief Summary

Trial is onging in other countries

Detailed Description

Not available

Study Timeline

• Study Completion: 2018-02-28
• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 18

Inclusion Criteria

- Fulfilling the EFNS/PNS criteria of propable or definite MMN
- Age >= 18 years.
- Stable on IVIG maintenance treatment in the year preceding the study.

Exclusion Criteria

- Treatment with other immunosuppressive drugs (cyclophosphamide, azathioprine, cyclosporine) in the 6 months preceding the study.
- Female patient who is pregnant or breast-feeding or of childbearing potential.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Safety/tolerability of hyqvia compared to IVIg<br /><br>Clinical effect of hyqvia compared to IVIg. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>none</p><br>